Mutations in CHEK2 associated with prostate cancer risk

American Journal of Human Genetics

Volumn 72, Issue 2, 2003, Pages 270-280

  Dong, Xiangyang ^a   Wang, Liang ^a   Taniguchi, Ken ^a   Wang, Xianshu ^a   Cunningham, Julie M ^a   McDonnell, Shannon K ^a   Qian, Chiping ^a   Marks, Angela F ^a   Slager, Susan L ^a   Peterson, Brett J ^a   Smith, David I ^a   Cheville, John C ^a   Blute, Michael L ^a   Jacobsen, Steve J ^a   Schaid, Daniel J ^a   Tindall, Donald J ^a   Thibodeau, Stephen N ^a   Liu, Wanguo ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CARCINOGENESIS; CHEK2 GENE; CONTROLLED STUDY; DNA DAMAGE; EPSTEIN BARR VIRUS; FAMILIAL CANCER; FRAMESHIFT MUTATION; GENE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS CELL TRANSFORMATION; WESTERN BLOTTING;

HUMAN HERPESVIRUS 4;

EID: 0037320555     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/346094     Document Type: Article

References (45)

1. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R (2001) Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 85:209-212
2. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531
3. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ (2000) Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67:82-91
4. Birch JM, Hartley AL, Blair V, Kelsey AM, Harris M, Teare MD, Jones PH (1990) Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J Clin Oncol 8:583-590
5. Birch JM, Hartley AL, Marsden HB, Harris M, Swindell R (1984) Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 49:325-331
6. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298-1304
7. Boddy MN, Furnari B, Mondesert O, Russell P (1998) Replication checkpoint enforced by kinases Cds1 and Chk1. Science 280:909-912
8. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace AJ Jr (2001) Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411:102-107
9. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, et al (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30:181-184
10. Caspari T (2000) How to activate p53. Curr Biol 10: R315-R317
11. Durocher D, Taylor IA, Sarbassova D, Haire LF, Westcott SL, Jackson SP, Smerdon SJ, Yaffe MB (2000) The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol Cell 6:1169-1182
12. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842-847
13. Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C (2000) Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Ther 7:1307-1314
14. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692-695
15. Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA (2000) The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 60:4513-4518
16. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824-1827
17. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366-374
18. Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247-254
19. Koivisto PA, Rantala I (1999) Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 187:237-241
20. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362
21. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ (2002) Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 9:1045-1054
22. Liu W, Oefner PJ, Qian C, Odom RS, Francke U (1997) Denaturing HPLC-identified novel FBN1 mutations, polymorphisms, and sequence variants in Marfan syndrome and related connective tissue disorders. Genet Test 1:237-242
23. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
24. Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893-1897
25. Matsuoka S, Nakagawa T, Masuda A, Haruki N, Elledge SJ, Takahashi T (2001) Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res 61:362-5365
26. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59
27. Melton LJ 3rd (1996) History of the Rochester Epidemiology Project. Mayo Clin Proc 71:266-274
28. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
29. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S, Koeffler HP (2002) Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 33:17-21
30. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860-864
31. Ostrander EA, Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67:1367-1375
32. Paulovich AG, Hartwell LH (1995) A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 82:841-847
33. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB (2000) Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 67:1014-1019
34. Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ (2000) Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997. Urology 56:817-822
35. Sanchez Y, Desany BA, Jones WJ, Liu Q, Wang B, Elledge SJ (1996) Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways. Science 271:357-360
36. Sasieni PD (1997) From genotypes to genes: doubling the sample size. Biometrics 53:1253-1261
37. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-1753
38. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289-300
39. Slager SL, Schaid DJ (2001) Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet 68:1457-1462
40. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Rova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Issacs WB (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374
41. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, et al (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27:172-180
42. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718-5722
43. Voelkel-Johnson C, Voeks DJ, Greenberg NM, Barrios R, Maggouta F, Kurtz DT, Schwartz DA, Keller GM, Papenbrock T, Clawson GA, Norris JS (2000) Genomic instability-based transgenic models of prostate cancer. Carcinogenesis 21:1623-627
44. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2001) Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 61:6494-6499
45. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001) Evaluation of linkage and association of HPC2/ ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 68:901-911